

Freedom of Information Request	FOI 21-250	2 nd July 2021
--------------------------------	------------	---------------------------

We are investigating the incidence and treatment of different types of cancer in the UK. We would greatly appreciate if you could answer the following three questions:

- 1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?**
 - Carboplatin (monotherapy or in combination with 5-FU)
 - Cisplatin (monotherapy or in combination with 5-FU)
 - Cetuximab with/without chemotherapy
 - Cetuximab with radiotherapy
 - Pembrolizumab monotherapy
 - Pembrolizumab with chemotherapy
 - Nivolumab
 - Docetaxel (monotherapy or in combination with 5-FU)
 - Fluorouracil (5FU)
 - Radiotherapy only
 - Other

- 2. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer (squamous cell carcinoma)? If so, can you please provide the name of each trial along with the number of patients taking part?**

- 3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?**
 - Aflibercept
 - Bevacizumab
 - Capecitabine
 - CAPIRI
 - CAPOX (XELOX)
 - Cetuximab in combination with FOLFIRI
 - Cetuximab in combination with FOLFOX
 - Cetuximab not in combination with FOLFIRI or FOLFOX
 - Irinotecan only
 - FOLFIRI
 - FOLFOX
 - Fluorouracil (5FU) only
 - Oxaliplatin only
 - Panitumumab in combination with FOLFIRI

- **Panitumumab in combination with FOLFOX**
 - **Panitumumab not in combination with FOLFIRI or FOLFOX**
 - **Nivolumab**
 - **Raltitrexed**
 - **Ramucirumab**
 - **Regorafenib**
 - **Sorafenib**
- Other SACT**

All of the Health Boards Head and Neck and Colorectal chemotherapy and radiotherapy is delivered by Velindre University NHS Trust, therefore you will need to contact via the following link: <https://velindre.nhs.wales/about-us/publications/freedom-of-information/>